Developer docs
API playgroundTry for free, no card

Search company profiles

NGeneBio

Full company profile

uuid0003imx

Namestring
NGeneBio
Legal namestring
주식회사 엔젠바이오
Websiteurl
ngenebio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

NGeneBio (KOSDAQ: 354200) is a publicly listed South Korean precision diagnostics company that develops and commercializes next-generation sequencing (NGS)-based in vitro diagnostic (IVD) panels, bioinformatics analysis software, and hospital-integrated genomic information systems. The company serves large university hospitals, clinical laboratories, pharmaceutical companies, and—through its 'na-e' mobile application—general consumers in South Korea and across 28 international markets including Vietnam (where it holds #1 market share as of February 2025), Saudi Arabia, UAE, and the United States, where it operates two CLIA-certified laboratories acquired in 2024. Leadership is headed by CEO Kim Min-sik, with a newly appointed Chief Data Officer (Jenny Song, Ph.D., ex-Spark Therapeutics) driving a genomic data licensing business launched in 2025.

Its product portfolio spans oncology precision panels (BRCAaccuTest, HEMEaccuTest, ONCOaccuPanel covering 344+ genes, SOLIDaccuTest, MRDaccuPanel AML FLT3), infection diagnostics (MTBaccuPanel for tuberculosis, NGenePlex nCoV/FluA.B), HLA tissue-typing kits (HLAaccuTest), and software including NGeneAnalySys (NGAS) with 20+ integrated databases, EasyHLAanalyzer, and the AI-powered NPAS pathology analysis tool. The company holds multiple MFDS and CE-IVD certifications, including several first-in-Korea and first-in-Asia approvals dating back to 2017. The NGLIS system integrates hospital EMR with genomic workflows and was deployed at Seoul Asan Hospital in November 2024; the G-Hub platform consolidates multimodal clinical, genomic, and pathology data for AI-driven decision support and real-world evidence research. NGeneBio's AI capabilities are anchored by a January 2026 license to LG AI Research's EXAONE Path 2.0 EGFR prediction model.

NGeneBio monetizes through one-time IVD kit and reagent sales, software licenses, recurring NGLIS system maintenance, DTC genetic testing subscriptions, and—since September 2025—a pharmaceutical distribution business acquired through subsidiary EngenPharma (formerly Nuripharma). Consolidated 2025 revenue reached 21.24 billion KRW with 278.5% year-over-year growth, though this is materially inflated by the EngenPharma consolidation; standalone diagnostic-segment revenue grew approximately 36% year-over-year in Q1 2026. The company remains unprofitable (8.3 billion KRW operating loss in 2025) and announced a ~224 billion KRW rights offering in June 2026 to fund AI platform development, NGLIS expansion, and debt reduction.

Short descriptiontext

NGeneBio is a KOSDAQ-listed South Korean precision diagnostics company developing NGS-based IVD panels, bioinformatics software, and hospital genomic information systems for hospitals, laboratories, pharmaceutical companies, and consumers across 28 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NGS diagnostic panels, precision oncology diagnostics, clinical bioinformatics software, companion diagnostic tests, liquid biopsy diagnostics
Industry4 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model6 records
1Precision Diagnostic Products (NGS Panels)
TypeOne Time License
Description

Sale of IVD-certified NGS-based precision diagnostic panels including BRCAaccuTest, HEMEaccuTest, ONCOaccuPanel, SOLIDaccuTest, HLAaccuTest, and infection diagnosis kits to hospitals and clinical laboratories domestically and internationally. Revenue from product kit sales and reagent supply.

ngenebio.com
2Analysis Software (NGeneAnalySys, EasyHLAanalyzer)
TypeOne Time License
Description

Sale and supply of bioinformatics analysis software for precision diagnostic panels, providing variant detection, interpretation, and clinical reporting. Software provided as local server-based solution to hospitals and laboratories.

ngenebio.com
3NGLIS Hospital Integrated Information System
TypeSubscription Recurring
Description

Construction and supply of NGLIS integrated genomic information management systems to major university hospitals in Korea, creating system build revenue and ongoing software maintenance/support revenue.

ngenebio.com
4DTC Genetic Testing Services
TypeSubscription Recurring
Description

Direct-to-Consumer genetic testing services to general consumers through the 'na-e' mobile app, providing personalized health management solutions based on genetic analysis and microbiome testing.

ngenebio.com
5Pharmaceutical Distribution (via subsidiary NGenePharma)
TypeManaged Services
Description

Specialty pharmaceutical distribution business through subsidiary NGenePharma (merged with Nuripharm in 2025), providing stable cash-cow revenue. NGenePharma contributed approximately 10.36 billion KRW in quarterly revenue (Q1 2026) and 103.6 billion KRW in annual sales in 2025.

ngenebio.com
6Genome Data Licensing and AI Services
TypeData Monetisation
Description

Plans to license Korean/Asian genomic datasets to global pharmaceutical and biotech companies for drug discovery and precision medicine research, with newly appointed CDO Jenny Song (Ph.D.) leading data business expansion. Participation in Bio USA 2026 for global genomic data partnership discussions.

ngenebio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 16 records shown
1BRCAaccuTest / BRCAaccuTest PLUS
Description

NGS-based precision diagnostic panel for hereditary breast and ovarian cancer (BRCA1/2 genes). First Korea MFDS and first-in-Asia CE-IVD approved.

ngenebio.com
+15 more records
Core offering1 text field

NGeneBio develops, manufactures, and commercializes IVD-certified NGS-based precision diagnostic panels and reagent kits for cancer (solid tumor and hematological malignancies), tissue compatibility (HLA), and infectious diseases, along with bioinformatics analysis software (NGeneAnalySys, EasyHLAanalyzer, NPAS) and integrated hospital genomic information management systems (NGLIS, G-Hub). The company supplies these products and platforms to hospitals, clinical laboratories, and pharmaceutical companies globally, while also operating US CLIA labs and a direct-to-consumer genetic testing mobile service.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • MRD detection rate improvement from ~8% to ~53% (6x improvement) using MRDaccuPanel AML FLT3 compared to fragment analysis, achieving VAF 0.001% sensitivity per ELN guidelines.
+4 more records
Product overview1 text field

NGeneBio is a multi-product precision medicine platform company offering an integrated portfolio of NGS-based diagnostic kits, bioinformatics analysis software, and hospital-integrated data management systems. The portfolio consists of: (1) precision diagnostic panels (BRCAaccuTest, HEMEaccuTest, ONCOaccuPanel, SOLIDaccuTest, HLAaccuTest, MRDaccuPanel AML FLT3) for hereditary cancer, solid tumor, hematological malignancy, and tissue compatibility testing; (2) infection diagnostic products (NGenePlex nCoV/FluA.B Detection Kit, MTBaccuPanel); (3) analysis software platforms (NGeneAnalySys/NGAS for variant detection/interpretation, EasyHLAanalyzer for HLA genotyping, NPAS for AI pathology image analysis); and (4) integrated hospital information systems (NGLIS for genomic laboratory workflow management, G-Hub for multimodal AI precision medicine data platform). Products are regulated medical devices with MFDS and/or CE-IVD certifications. The platform integrates with hospital EMR systems and connects to Illumina sequencing instruments.

Product and service15 records
1BRCAaccuTest / BRCAaccuTest PLUS
CategoryPrecision Diagnostic Product
Description

NGS-based precision diagnostic panel for detecting BRCA1 and BRCA2 gene variants (SNV, INDEL, CNV) in hereditary breast and ovarian cancer patients. The PLUS version adds expanded target regions for CNV detection and improved data uniformity. MFDS and CE-IVD certified. First Korea MFDS and first-in-Asia CE-IVD approved product.

2HEMEaccuTest DNA / RNA
CategoryPrecision Diagnostic Product
Description

NGS-based precision diagnostic panel detecting approximately 100 gene variants associated with hematological malignancies including AML, ALL, MDS/MPN, MM, and lymphoma. DNA panel targets SNV/INDEL; RNA panel targets structural variants (fusions). CE-IVD certified.

3ONCOaccuPanel
CategoryPrecision Diagnostic Product
Description

Large-panel pan-cancer NGS diagnostic product analyzing 344 genes from solid tumor FFPE/tissue specimens, detecting SNV, INDEL, CNV, SV (Fusion), TMB, and MSI for 35+ solid cancer types. Technology transferred from Seoul Asan Hospital and Harvard Dana-Farber Cancer Institute. CE-IVD certified.

4SOLIDaccuTest DNA / RNA / HRD
CategoryPrecision Diagnostic Product
Description

NGS-based solid cancer precision diagnostic panel targeting approximately 100 genes (84 genes DNA, 29 genes RNA, 111 genes HRD) for detecting mutations (SNV, INDEL, CNV) and NTRK gene fusions in lung, colorectal, gastric, and breast cancers. MFDS and CE-IVD certified.

5HLAaccuTest / HLAaccuTest All
CategoryPrecision Diagnostic Product
Description

NGS-based tissue compatibility (HLA) genotyping test for donor-recipient matching in organ and bone marrow transplantation, identifying HLA-A, B, C, DRB1, DQB1, DRB3/4/5, DQA1, DPA1, DPB1 alleles at high resolution. MFDS and CE-IVD certified.

6MRDaccuPanel AML FLT3
CategoryPrecision Diagnostic Product
Description

NGS-based minimal residual disease (MRD) diagnostic panel for acute myeloid leukemia (AML), detecting FLT3 gene ITD and TKD variants at 0.001% VAF sensitivity. Achieves MRD detection rate improvement from ~8% to ~53% (6x improvement) compared to fragment analysis per ELN guidelines. MFDS export manufacturing approval obtained.

7NGenePlex nCoV qRT-PCR Kit
CategoryInfection Diagnostic Product
Description

Real-time RT-PCR diagnostic kit for qualitative detection of SARS-CoV-2 (COVID-19) nucleic acid from respiratory specimens. CE-IVD and MFDS export approval certified.

8NGenePlex nCoV/FluA.B Detection Kit
CategoryInfection Diagnostic Product
Description

Real-time RT-PCR-based in vitro diagnostic kit for simultaneous qualitative detection of SARS-CoV-2, Influenza A, and Influenza B from respiratory specimens. CE-IVD and MFDS export approval certified.

9MTBaccuPanel
CategoryInfection Diagnostic Product
Description

NGS-based diagnostic kit for simultaneous identification of mycobacteria and detection of tuberculosis drug-resistance mutations. Developed for respiratory infectious disease diagnostics and pandemic preparedness.

10NGeneAnalySys (NGAS)
CategoryAnalysis Software
Description

Local server-based bioinformatics analysis software for precision diagnostic panels that performs automated variant detection, annotation, and clinical interpretation using 20+ validated databases and ACMG/AMP guidelines, providing one-stop NGS data analysis, variant reporting, and QC report generation.

11EasyHLAanalyzer
CategoryAnalysis Software
Description

HLA genotyping analysis software that applies bioinformatics algorithms based on IMGT/HLA database to perform NGS data-based HLA typing, supporting genotype results review, coverage/VAF confirmation, and clinical reporting for organ and bone marrow transplantation compatibility testing.

12NGLIS (Next-Generation Genomic Laboratory Information System)
CategoryIntegrated Information System
Description

Hospital-integrated genomic laboratory information system that connects EMR and genomic analysis software into a single platform, automating genomic testing workflows from order to data analysis, quality management, and clinical reporting using SOP-based standardization.

13G-Hub Platform
CategoryIntegrated Information System
Description

Next-generation precision medicine platform integrating multimodal data including genomics (NGS), clinical records (EMR), and pathology, standardized to international formats for AI-ready datasets, powering biomarker-based clinical matching, RWE research analytics, and AI decision support.

14NPAS (NPathAnalySys)
CategoryAnalysis Software
Description

AI pathology analysis software that processes histopathological tissue images to predict gene mutation probability, using deep learning models including the licensed EXAONE Path 2.0 EGFR variant prediction model, enabling AI + NGS hybrid cancer diagnosis workflows.

15na-e Health Management App
CategoryHealthcare Service
Description

Direct-to-consumer mobile health management application providing personalized health services including dietary, lifestyle habit, and microbiome analysis, integrated with personal genetic testing and health coaching. Offers 70 certified DTC genetic testing items approved by the Ministry of Health and Welfare.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
1Catholic University Yeouido St. Mary's Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

Joint research agreement for AI·NGS integrated companion diagnosis solution clinical evaluation, signed June 2026. Professor Tae-Jung Kim from the hospital's Pathology Department leads clinical research comparing NGeneBio's AI·NGS solution against global standard Oncoman companion diagnostic products. Plans to file for digital medical device approval by end of 2026.

ngenebio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Three-party MOU for MRD (Minimal Residual Disease) precision diagnosis technology advancement, signed March 2026. NGeneBio provides NGS-based genomic analysis and bioinformatics software; Catholic University Seoul St. Mary's Hospital provides clinical expertise and AML patient samples; YatiriBio (San Diego, proteomics/AI biomarker company) contributes AI-based multi-omics analysis with 5,500+ drug response datasets.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

License agreement for 'EXAONE Path 2.0' EGFR mutation prediction AI model in January 2026. The AI model was applied to NPAS-EGFR, NGeneBio's first AI pathology analysis model, as part of the AI·NGS integrated companion diagnosis solution developed with Catholic University Yeouido St. Mary's Hospital.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Selected for '2025 Medical AI Data Utilization Voucher Support Project' hosted by KHIDI (Korea Health Industry Development Institute), to develop next-generation immunotherapy response prediction AI solution with Yonsei Medical Center.

5CosmaxBio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Strategic business agreement signed September 2025 with CosmaxBio for gene data-based next-generation health functional food co-development and global market entry.

ngenebio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Strategic business agreement signed July 2025 with global diagnostics and life sciences company Agilent Technologies Korea to expand AI SW-based genomic analysis business.

7CILab
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Strategic partnership signed April 2025 with Vision AI company CILab for AI-based customized cancer treatment and prediction platform development.

ngenebio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Strategic business agreement signed February 2025 with in vitro diagnostic technology company QuantaMatrix for dementia diagnosis field.

9Lag3 Genomics (LabGenomics)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-01
Description

NGS diagnostic service development and business cooperation agreement signed December 2022 with Lag3 Genomics through US CLIA lab.

ngenebio.com
10Seoul Asan Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Co-developed NGLIS (Next-Generation Genomic Laboratory Information System) which achieved commercial launch and operation at Seoul Asan Hospital in November 2024. Exclusive technology transfer agreement for NGLIS signed in January 2026.

ngenebio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Selected as a participating company in the WHO-PQ (WHO Pre-qualification) clinical performance test technical support project for in vitro diagnostic medical devices, August 2024.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Partnership for NGS-based precision diagnostics business expansion and targeted anticancer drug prescription expansion. Joint online symposium on NTRK gene fusion and NGS precision diagnostics held October 2024.

13Euro Alliance (EA), UAE
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-01
Description

Technology transfer agreement signed April 2024 for NGS-based precision diagnostic medical device manufacturing technology and lab service know-how to UAE-based Euro Alliance (EA) company.

ngenebio.com
14UroOuri Children & Women Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Microbiome curation platform business agreement signed February 2022 with UroOuri Children & Women Hospital.

ngenebio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Strategic business agreement signed March 2024 with molecular diagnostics company Genolution.

16Vertyis
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic business agreement signed January 2024 with proteomics-based precision medicine company Vertyis for multi-omics-based AI early diagnosis technology development and commercialization.

ngenebio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Participated as a member of CancerX under the US Biden administration's Cancer Moonshot initiative since October 2023.

18KeyPleeShop / KT Alpha
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-09-01
Description

Partnership with KT Alpha mobile coupon service KeyPleeShop for Mendels DTC 45 genetic testing analysis kit launch and sales in September 2022.

ngenebio.com
Strategic tierMinorTypeOthersAnnounced on2022-05-01
Description

Healthcare service provision business agreement signed May 2022 with Hana Bank.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

NGS-based companion diagnostics technology development business agreement signed January 2021 with ParosIBIO.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Guardant Health is a US-based precision oncology company specializing in NGS-based liquid biopsy and blood-based cancer diagnostics, directly comparable to NGeneBio's ctDNA/MRD panels (MRDaccuPanel AML FLT3, BRCAaccuTest). Both compete in NGS liquid biopsy for cancer detection, MRD monitoring, and treatment selection.

TypeDirect peer
Description

Foundation Medicine (a Roche subsidiary) is a leading NGS-based comprehensive genomic profiling company for solid tumors, directly comparable to NGeneBio's ONCOaccuPanel (344 genes) and SOLIDaccuTest products. Both serve pharma companion diagnostic needs and oncology clinical decision-making.

3Tempus AI
TypeDirect peer
Description

Tempus AI combines NGS-based molecular profiling with multimodal data (pathology, clinical, RWE) for precision medicine, directly comparable to NGeneBio's G-Hub multimodal AI platform and NPAS AI pathology offering. Both target pharma data partnerships and AI-enabled clinical decision support.

TypeDirect peer
Description

Burning Rock Biotech is a China-based NGS precision oncology company offering cancer gene detection panels and companion diagnostics, closely comparable to NGeneBio's NGS panel portfolio and Asian-market go-to-market approach. Both target cancer diagnostics with focus on Asian patient populations.

TypeRegional player
Description

Macrogen is a Korea-headquartered genomic services and NGS company with global operations. Comparable to NGeneBio in NGS-based services, Korean/Asian genomic data assets, and bioinformatics software (NGeneAnalySys vs Macrogen's analysis platforms). Both operate in the Korean precision diagnostics ecosystem.

TypeDirect peer
Description

Personalis is a US-based NGS cancer genomics company offering tumor profiling and MRD detection, directly comparable to NGeneBio's MRDaccuPanel and solid tumor panels. Both serve pharma CDx development and clinical oncology with NGS-based solutions.

TypeBroad incumbent
Description

NeoGenomics is a US-based clinical laboratory and oncology diagnostics provider offering NGS-based cancer testing, comparable to NGeneBio's US CLIA lab operations (TOPLAB NJ, San Diego). Both serve hospital and pharma clients with NGS-based oncology diagnostics.

8MGI Tech
TypeEmerging player
Description

MGI Tech is a China-based global NGS sequencing platform and IVD company with which NGeneBio has a business agreement (Aug 2023). Comparable through NGS instrument/reagent ecosystem and Asian-market diagnostic panels, making MGI both a partner and adjacent competitor.

TypeRegional player
Description

Genomedia is a Korean molecular diagnostics and NGS services company, comparable to NGeneBio as a Korean domestic NGS diagnostics competitor. Both target Korean university hospitals with NGS-based cancer panels.

TypeBroad incumbent
Description

Agilent Technologies is a global life sciences and diagnostics company with which NGeneBio has a strategic business agreement (Jul 2025). Comparable through analytical laboratory instruments, genomics workflows, and bioinformatics software, making Agilent both a partner and broad incumbent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NGeneBio

Molecular Diagnosticsngenebio.com

NGeneBio is a KOSDAQ-listed South Korean precision diagnostics company developing NGS-based IVD panels, bioinformatics software, and hospital genomic information systems for hospitals, laboratories, pharmaceutical companies, and consumers across 28 countries.

What NGeneBio does

NGeneBio (KOSDAQ: 354200) is a publicly listed South Korean precision diagnostics company that develops and commercializes next-generation sequencing (NGS)-based in vitro diagnostic (IVD) panels, bioinformatics analysis software, and hospital-integrated genomic information systems. The company serves large university hospitals, clinical laboratories, pharmaceutical companies, and—through its 'na-e' mobile application—general consumers in South Korea and across 28 international markets including Vietnam (where it holds #1 market share as of February 2025), Saudi Arabia, UAE, and the United States, where it operates two CLIA-certified laboratories acquired in 2024. Leadership is headed by CEO Kim Min-sik, with a newly appointed Chief Data Officer (Jenny Song, Ph.D., ex-Spark Therapeutics) driving a genomic data licensing business launched in 2025.

Its product portfolio spans oncology precision panels (BRCAaccuTest, HEMEaccuTest, ONCOaccuPanel covering 344+ genes, SOLIDaccuTest, MRDaccuPanel AML FLT3), infection diagnostics (MTBaccuPanel for tuberculosis, NGenePlex nCoV/FluA.B), HLA tissue-typing kits (HLAaccuTest), and software including NGeneAnalySys (NGAS) with 20+ integrated databases, EasyHLAanalyzer, and the AI-powered NPAS pathology analysis tool. The company holds multiple MFDS and CE-IVD certifications, including several first-in-Korea and first-in-Asia approvals dating back to 2017. The NGLIS system integrates hospital EMR with genomic workflows and was deployed at Seoul Asan Hospital in November 2024; the G-Hub platform consolidates multimodal clinical, genomic, and pathology data for AI-driven decision support and real-world evidence research. NGeneBio's AI capabilities are anchored by a January 2026 license to LG AI Research's EXAONE Path 2.0 EGFR prediction model.

NGeneBio monetizes through one-time IVD kit and reagent sales, software licenses, recurring NGLIS system maintenance, DTC genetic testing subscriptions, and—since September 2025—a pharmaceutical distribution business acquired through subsidiary EngenPharma (formerly Nuripharma). Consolidated 2025 revenue reached 21.24 billion KRW with 278.5% year-over-year growth, though this is materially inflated by the EngenPharma consolidation; standalone diagnostic-segment revenue grew approximately 36% year-over-year in Q1 2026. The company remains unprofitable (8.3 billion KRW operating loss in 2025) and announced a ~224 billion KRW rights offering in June 2026 to fund AI platform development, NGLIS expansion, and debt reduction.

NGeneBio firmographics

Firmographics
Name
NGeneBio
Legal name
주식회사 엔젠바이오
Website
https://ngenebio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NGeneBio is a KOSDAQ-listed South Korean precision diagnostics company developing NGS-based IVD panels, bioinformatics software, and hospital genomic information systems for hospitals, laboratories, pharmaceutical companies, and consumers across 28 countries.
Ownership category
akta.pro rank

NGeneBio industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • NGS diagnostic panels
  • Precision oncology diagnostics
  • Clinical bioinformatics software
  • Companion diagnostic tests
  • Liquid biopsy diagnostics

Where NGeneBio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices6 records

Markets served

NGeneBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Precision Diagnostic Products (NGS Panels): Sale of IVD-certified NGS-based precision diagnostic panels including BRCAaccuTest, HEMEaccuTest, ONCOaccuPanel, SOLIDaccuTest, HLAaccuTest, and infection diagnosis kits to hospitals and clinical laboratories domestically and internationally. Revenue from product kit sales and reagent supply.
  2. Analysis Software (NGeneAnalySys, EasyHLAanalyzer): Sale and supply of bioinformatics analysis software for precision diagnostic panels, providing variant detection, interpretation, and clinical reporting. Software provided as local server-based solution to hospitals and laboratories.
  3. NGLIS Hospital Integrated Information System: Construction and supply of NGLIS integrated genomic information management systems to major university hospitals in Korea, creating system build revenue and ongoing software maintenance/support revenue.
  4. DTC Genetic Testing Services: Direct-to-Consumer genetic testing services to general consumers through the 'na-e' mobile app, providing personalized health management solutions based on genetic analysis and microbiome testing.
  5. Pharmaceutical Distribution (via subsidiary NGenePharma): Specialty pharmaceutical distribution business through subsidiary NGenePharma (merged with Nuripharm in 2025), providing stable cash-cow revenue. NGenePharma contributed approximately 10.36 billion KRW in quarterly revenue (Q1 2026) and 103.6 billion KRW in annual sales in 2025.
  6. Genome Data Licensing and AI Services: Plans to license Korean/Asian genomic datasets to global pharmaceutical and biotech companies for drug discovery and precision medicine research, with newly appointed CDO Jenny Song (Ph.D.) leading data business expansion. Participation in Bio USA 2026 for global genomic data partnership discussions.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

NGeneBio product offering

Product offering

Core offering

NGeneBio develops, manufactures, and commercializes IVD-certified NGS-based precision diagnostic panels and reagent kits for cancer (solid tumor and hematological malignancies), tissue compatibility (HLA), and infectious diseases, along with bioinformatics analysis software (NGeneAnalySys, EasyHLAanalyzer, NPAS) and integrated hospital genomic information management systems (NGLIS, G-Hub). The company supplies these products and platforms to hospitals, clinical laboratories, and pharmaceutical companies globally, while also operating US CLIA labs and a direct-to-consumer genetic testing mobile service.

Product overview

NGeneBio is a multi-product precision medicine platform company offering an integrated portfolio of NGS-based diagnostic kits, bioinformatics analysis software, and hospital-integrated data management systems. The portfolio consists of: (1) precision diagnostic panels (BRCAaccuTest, HEMEaccuTest, ONCOaccuPanel, SOLIDaccuTest, HLAaccuTest, MRDaccuPanel AML FLT3) for hereditary cancer, solid tumor, hematological malignancy, and tissue compatibility testing; (2) infection diagnostic products (NGenePlex nCoV/FluA.B Detection Kit, MTBaccuPanel); (3) analysis software platforms (NGeneAnalySys/NGAS for variant detection/interpretation, EasyHLAanalyzer for HLA genotyping, NPAS for AI pathology image analysis); and (4) integrated hospital information systems (NGLIS for genomic laboratory workflow management, G-Hub for multimodal AI precision medicine data platform). Products are regulated medical devices with MFDS and/or CE-IVD certifications. The platform integrates with hospital EMR systems and connects to Illumina sequencing instruments.

Differentiator

Problem solved

Functional benefit

Brands

  • BRCAaccuTest / BRCAaccuTest PLUS: NGS-based precision diagnostic panel for hereditary breast and ovarian cancer (BRCA1/2 genes). First Korea MFDS and first-in-Asia CE-IVD approved.
  • HEMEaccuTest
  • ONCOaccuPanel
  • SOLIDaccuTest
  • HLAaccuTest / HLAaccuTest All
  • NGenePlex
  • MTBaccuPanel
  • NGeneAnalySys (NGAS)
  • EasyHLAanalyzer
  • NGLIS
  • G-Hub Platform
  • NPAS (NPathAnalySys)
  • MRDaccuPanel
  • na-e (나에)
  • WELFIT
  • NGeneBio

Products and services

  • BRCAaccuTest / BRCAaccuTest PLUS NGS-based precision diagnostic panel for detecting BRCA1 and BRCA2 gene variants (SNV, INDEL, CNV) in hereditary breast and ovarian cancer patients. The PLUS version adds expanded target regions for CNV detection and improved data uniformity. MFDS and CE-IVD certified. First Korea MFDS and first-in-Asia CE-IVD approved product.
  • HEMEaccuTest DNA / RNA NGS-based precision diagnostic panel detecting approximately 100 gene variants associated with hematological malignancies including AML, ALL, MDS/MPN, MM, and lymphoma. DNA panel targets SNV/INDEL; RNA panel targets structural variants (fusions). CE-IVD certified.
  • ONCOaccuPanel Large-panel pan-cancer NGS diagnostic product analyzing 344 genes from solid tumor FFPE/tissue specimens, detecting SNV, INDEL, CNV, SV (Fusion), TMB, and MSI for 35+ solid cancer types. Technology transferred from Seoul Asan Hospital and Harvard Dana-Farber Cancer Institute. CE-IVD certified.
  • SOLIDaccuTest DNA / RNA / HRD NGS-based solid cancer precision diagnostic panel targeting approximately 100 genes (84 genes DNA, 29 genes RNA, 111 genes HRD) for detecting mutations (SNV, INDEL, CNV) and NTRK gene fusions in lung, colorectal, gastric, and breast cancers. MFDS and CE-IVD certified.
  • HLAaccuTest / HLAaccuTest All NGS-based tissue compatibility (HLA) genotyping test for donor-recipient matching in organ and bone marrow transplantation, identifying HLA-A, B, C, DRB1, DQB1, DRB3/4/5, DQA1, DPA1, DPB1 alleles at high resolution. MFDS and CE-IVD certified.
  • MRDaccuPanel AML FLT3 NGS-based minimal residual disease (MRD) diagnostic panel for acute myeloid leukemia (AML), detecting FLT3 gene ITD and TKD variants at 0.001% VAF sensitivity. Achieves MRD detection rate improvement from ~8% to ~53% (6x improvement) compared to fragment analysis per ELN guidelines. MFDS export manufacturing approval obtained.
  • NGenePlex nCoV qRT-PCR Kit Real-time RT-PCR diagnostic kit for qualitative detection of SARS-CoV-2 (COVID-19) nucleic acid from respiratory specimens. CE-IVD and MFDS export approval certified.
  • NGenePlex nCoV/FluA.B Detection Kit Real-time RT-PCR-based in vitro diagnostic kit for simultaneous qualitative detection of SARS-CoV-2, Influenza A, and Influenza B from respiratory specimens. CE-IVD and MFDS export approval certified.
  • MTBaccuPanel NGS-based diagnostic kit for simultaneous identification of mycobacteria and detection of tuberculosis drug-resistance mutations. Developed for respiratory infectious disease diagnostics and pandemic preparedness.
  • NGeneAnalySys (NGAS) Local server-based bioinformatics analysis software for precision diagnostic panels that performs automated variant detection, annotation, and clinical interpretation using 20+ validated databases and ACMG/AMP guidelines, providing one-stop NGS data analysis, variant reporting, and QC report generation.
  • EasyHLAanalyzer HLA genotyping analysis software that applies bioinformatics algorithms based on IMGT/HLA database to perform NGS data-based HLA typing, supporting genotype results review, coverage/VAF confirmation, and clinical reporting for organ and bone marrow transplantation compatibility testing.
  • NGLIS (Next-Generation Genomic Laboratory Information System) Hospital-integrated genomic laboratory information system that connects EMR and genomic analysis software into a single platform, automating genomic testing workflows from order to data analysis, quality management, and clinical reporting using SOP-based standardization.
  • G-Hub Platform Next-generation precision medicine platform integrating multimodal data including genomics (NGS), clinical records (EMR), and pathology, standardized to international formats for AI-ready datasets, powering biomarker-based clinical matching, RWE research analytics, and AI decision support.
  • NPAS (NPathAnalySys) AI pathology analysis software that processes histopathological tissue images to predict gene mutation probability, using deep learning models including the licensed EXAONE Path 2.0 EGFR variant prediction model, enabling AI + NGS hybrid cancer diagnosis workflows.
  • na-e Health Management App Direct-to-consumer mobile health management application providing personalized health services including dietary, lifestyle habit, and microbiome analysis, integrated with personal genetic testing and health coaching. Offers 70 certified DTC genetic testing items approved by the Ministry of Health and Welfare.

Quantifiable outcome

  • MRD detection rate improvement from ~8% to ~53% (6x improvement) using MRDaccuPanel AML FLT3 compared to fragment analysis, achieving VAF 0.001% sensitivity per ELN guidelines.
  • +4 more outcomes

Companies that use NGeneBio

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

NGeneBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

NGeneBio partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core and minor.

  • Catholic University Yeouido St. Mary's HospitalcoreStrategic or Co-development Partner · 19 June 2026Joint research agreement for AI·NGS integrated companion diagnosis solution clinical evaluation, signed June 2026. Professor Tae-Jung Kim from the hospital's Pathology Department leads clinical research comparing NGeneBio's AI·NGS solution against global standard Oncoman companion diagnostic products. Plans to file for digital medical device approval by end of 2026.
  • Catholic University / YatiriBiocoreStrategic or Co-development Partner · 26 March 2026Three-party MOU for MRD (Minimal Residual Disease) precision diagnosis technology advancement, signed March 2026. NGeneBio provides NGS-based genomic analysis and bioinformatics software; Catholic University Seoul St. Mary's Hospital provides clinical expertise and AML patient samples; YatiriBio (San Diego, proteomics/AI biomarker company) contributes AI-based multi-omics analysis with 5,500+ drug response datasets.
  • LG AI ResearchcoreTechnology or Integration · 1 January 2026License agreement for 'EXAONE Path 2.0' EGFR mutation prediction AI model in January 2026. The AI model was applied to NPAS-EGFR, NGeneBio's first AI pathology analysis model, as part of the AI·NGS integrated companion diagnosis solution developed with Catholic University Yeouido St. Mary's Hospital.
  • Yonsei Medical CentercoreStrategic or Co-development Partner · 1 September 2025Selected for '2025 Medical AI Data Utilization Voucher Support Project' hosted by KHIDI (Korea Health Industry Development Institute), to develop next-generation immunotherapy response prediction AI solution with Yonsei Medical Center.
  • CosmaxBiominorStrategic or Co-development Partner · 1 September 2025Strategic business agreement signed September 2025 with CosmaxBio for gene data-based next-generation health functional food co-development and global market entry.
  • Agilent Technologies KoreaminorStrategic or Co-development Partner · 1 July 2025Strategic business agreement signed July 2025 with global diagnostics and life sciences company Agilent Technologies Korea to expand AI SW-based genomic analysis business.
  • CILabminorStrategic or Co-development Partner · 1 April 2025Strategic partnership signed April 2025 with Vision AI company CILab for AI-based customized cancer treatment and prediction platform development.
  • QuantaMatrixminorStrategic or Co-development Partner · 1 February 2025Strategic business agreement signed February 2025 with in vitro diagnostic technology company QuantaMatrix for dementia diagnosis field.
  • Lag3 Genomics (LabGenomics)minorChannel Partner/ Reseller/ Distributor · 1 December 2024NGS diagnostic service development and business cooperation agreement signed December 2022 with Lag3 Genomics through US CLIA lab.
  • Seoul Asan HospitalcoreStrategic or Co-development Partner · 1 November 2024Co-developed NGLIS (Next-Generation Genomic Laboratory Information System) which achieved commercial launch and operation at Seoul Asan Hospital in November 2024. Exclusive technology transfer agreement for NGLIS signed in January 2026.
  • WHO-PQ Clinical Performance StudyminorStrategic or Co-development Partner · 1 August 2024Selected as a participating company in the WHO-PQ (WHO Pre-qualification) clinical performance test technical support project for in vitro diagnostic medical devices, August 2024.
  • Bayer KoreacoreStrategic or Co-development Partner · 1 July 2024Partnership for NGS-based precision diagnostics business expansion and targeted anticancer drug prescription expansion. Joint online symposium on NTRK gene fusion and NGS precision diagnostics held October 2024.
  • Euro Alliance (EA), UAEminorChannel Partner/ Reseller/ Distributor · 1 April 2024Technology transfer agreement signed April 2024 for NGS-based precision diagnostic medical device manufacturing technology and lab service know-how to UAE-based Euro Alliance (EA) company.
  • UroOuri Children & Women HospitalminorStrategic or Co-development Partner · 1 April 2024Microbiome curation platform business agreement signed February 2022 with UroOuri Children & Women Hospital.
  • GenolutionminorStrategic or Co-development Partner · 1 March 2024Strategic business agreement signed March 2024 with molecular diagnostics company Genolution.
  • VertyisminorStrategic or Co-development Partner · 1 January 2024Strategic business agreement signed January 2024 with proteomics-based precision medicine company Vertyis for multi-omics-based AI early diagnosis technology development and commercialization.
  • Cancer MoonshotminorStrategic or Co-development Partner · 1 October 2023Participated as a member of CancerX under the US Biden administration's Cancer Moonshot initiative since October 2023.
  • KeyPleeShop / KT AlphaminorChannel Partner/ Reseller/ Distributor · 1 September 2022Partnership with KT Alpha mobile coupon service KeyPleeShop for Mendels DTC 45 genetic testing analysis kit launch and sales in September 2022.
  • Hana BankminorOthers · 1 May 2022Healthcare service provision business agreement signed May 2022 with Hana Bank.
  • ParosIBIOminorStrategic or Co-development Partner · 1 January 2021NGS-based companion diagnostics technology development business agreement signed January 2021 with ParosIBIO.

Scale indicators7 records

Recent moves9 records

Expansion highlights7 records

NGeneBio competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Guardant Health is a US-based precision oncology company specializing in NGS-based liquid biopsy and blood-based cancer diagnostics, directly comparable to NGeneBio's ctDNA/MRD panels (MRDaccuPanel AML FLT3, BRCAaccuTest). Both compete in NGS liquid biopsy for cancer detection, MRD monitoring, and treatment selection.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading NGS-based comprehensive genomic profiling company for solid tumors, directly comparable to NGeneBio's ONCOaccuPanel (344 genes) and SOLIDaccuTest products. Both serve pharma companion diagnostic needs and oncology clinical decision-making.
  • Tempus AI: Tempus AI combines NGS-based molecular profiling with multimodal data (pathology, clinical, RWE) for precision medicine, directly comparable to NGeneBio's G-Hub multimodal AI platform and NPAS AI pathology offering. Both target pharma data partnerships and AI-enabled clinical decision support.
  • Burning Rock Biotech: Burning Rock Biotech is a China-based NGS precision oncology company offering cancer gene detection panels and companion diagnostics, closely comparable to NGeneBio's NGS panel portfolio and Asian-market go-to-market approach. Both target cancer diagnostics with focus on Asian patient populations.
  • Personalis: Personalis is a US-based NGS cancer genomics company offering tumor profiling and MRD detection, directly comparable to NGeneBio's MRDaccuPanel and solid tumor panels. Both serve pharma CDx development and clinical oncology with NGS-based solutions.

Regional players

  • Macrogen: Macrogen is a Korea-headquartered genomic services and NGS company with global operations. Comparable to NGeneBio in NGS-based services, Korean/Asian genomic data assets, and bioinformatics software (NGeneAnalySys vs Macrogen's analysis platforms). Both operate in the Korean precision diagnostics ecosystem.
  • Genomedia: Genomedia is a Korean molecular diagnostics and NGS services company, comparable to NGeneBio as a Korean domestic NGS diagnostics competitor. Both target Korean university hospitals with NGS-based cancer panels.

Broad incumbents

  • NeoGenomics: NeoGenomics is a US-based clinical laboratory and oncology diagnostics provider offering NGS-based cancer testing, comparable to NGeneBio's US CLIA lab operations (TOPLAB NJ, San Diego). Both serve hospital and pharma clients with NGS-based oncology diagnostics.
  • Agilent Technologies: Agilent Technologies is a global life sciences and diagnostics company with which NGeneBio has a strategic business agreement (Jul 2025). Comparable through analytical laboratory instruments, genomics workflows, and bioinformatics software, making Agilent both a partner and broad incumbent.

Emerging players

  • MGI Tech: MGI Tech is a China-based global NGS sequencing platform and IVD company with which NGeneBio has a business agreement (Aug 2023). Comparable through NGS instrument/reagent ecosystem and Asian-market diagnostic panels, making MGI both a partner and adjacent competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NGeneBio social profiles

Digital presence

NGeneBio compliance and trust

Trust signal

Compliance6 records

NGeneBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NGeneBio leadership team

Management profile

Number of profiles

Profiles4 records

NGeneBio subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

NGeneBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NGeneBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NGeneBio

What does NGeneBio do?

NGeneBio develops, manufactures, and commercializes IVD-certified NGS-based precision diagnostic panels and reagent kits for cancer (solid tumor and hematological malignancies), tissue compatibility (HLA), and infectious diseases, along with bioinformatics analysis software (NGeneAnalySys, EasyHLAanalyzer, NPAS) and integrated hospital genomic information management systems (NGLIS, G-Hub). The company supplies these products and platforms to hospitals, clinical laboratories, and pharmaceutical companies globally, while also operating US CLIA labs and a direct-to-consumer genetic testing mobile service.

Is NGeneBio a public or private company?

NGeneBio is a public company. It is classified as public and is currently operating.

When was NGeneBio founded?

NGeneBio was founded in 2015. It employs 11 to 50 people.

Where is NGeneBio based?

NGeneBio is headquartered in Seoul, South Korea, in the Asia region.

How does NGeneBio make money?

Six revenue lines are on record. Precision Diagnostic Products (NGS Panels) is the primary driver. The others are analysis Software (NGeneAnalySys, EasyHLAanalyzer), NGLIS Hospital Integrated Information System, DTC Genetic Testing Services, pharmaceutical Distribution (via subsidiary NGenePharma) and genome Data Licensing and AI Services.

Who are NGeneBio's main competitors?

Direct peers on record are Guardant Health, Foundation Medicine, Tempus AI, Burning Rock Biotech and Personalis. Regional players are Macrogen and Genomedia. Broad incumbents are NeoGenomics and Agilent Technologies. MGI Tech is listed as an emerging player.

Does NGeneBio have an API?

No public API is recorded for NGeneBio.

What industry is NGeneBio in?

NGeneBio's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChosunbizNGeneBio signs tech transfer with Asan Medical Center to streamline genomic dataNGeneBio, a South Korean precision diagnostics company specializing in next-generation sequencing (NGS), signed an exclusive technology transfer agreement with Asan Medical Center for the co-developed "next-generation laboratory information system" (NGLIS), an information management platform that integrates electronic medical records with genome analysis software. The system automates genetic testing workflows, consolidates clinical and genomic data into a single workflow, and enables simultaneous DNA and RNA analysis. NGeneBio plans to integrate NGLIS with its in-house "G-Hub" multimodal medical data platform and expand the combined system to hospitals across Asia, including Vietnam and Thailand, while building data-driven services for pharmaceutical and biotech companies.KedglobalNGeneBio applies for US patent of early diagnosis tech of dementia - KED GlobalNGeneBio applied for a US patent on its blood-based dementia diagnosis technology, detecting microRNA without cerebrospinal fluid collection. The company aims to enter the $1.5 billion US Alzheimer's market, combining Parkinson's and Lewy body dementia biomarkers with AI. It plans to commercialize tests via a CLIA lab it is acquiring.PR Newswire APACMGI Partners with NGeneBio to Advance Precision MedicineMGI and NGeneBio signed an MOU to expand global commercial access to NGeneBio's cancer testing products. The partnership integrates NGeneBio's NGS assays with MGI's DNBSEQ-G99 platform and will collaborate on APAC clinical trials. The companies aim to make precision diagnostics more accessible and cost-effective.The Korea HeraldKT, NGeneBio sign deal for genetic data-based digital health care serviceKT signed an MOU with NGeneBio to jointly develop a personalized health care product based on genetic data analysis. The collaboration will leverage KT's AI, big data, and cloud computing expertise with NGeneBio's genetic decoding, covering personalized coaching, data storage, and big data analysis. KT's 'digital bio' is a core part of its future business strategy.